02-13-2026 | Inflation data, tariff tensions and AI competition reshape today’s economic landscape

COMPANIES. Moderna faces Food and Drug Administration setback on flu vaccine. Moderna confirmed that the United States Food and Drug Administration refused to file its biologics license application for its messenger RNA influenza vaccine. The agency cited concerns about the Phase Three comparator design, not safety or efficacy. Moderna will seek a meeting with regulators and continue submissions outside the United States. The decision delays a potential new revenue stream in the respiratory market. THE ECONOMY. Markets await January Consumer Price Index data. The Bureau of Labor Statistics releases the January Consumer Price Index today. Economists project a monthly increase and closely watch core inflation. The data will shape expectations for Federal Reserve interest rates. Investors focus on whether inflation shows renewed momentum at the start of the year. POLITICS. House votes to overturn Canada tariffs. The United States House passed a resolution to rescind tariffs on Canadian imports. Six Republicans joined Democrats in the vote. The measure now heads to the Senate and could face a presidential veto. INNOVATION. China prepares wave of low cost artificial intelligence models. One year after DeepSeek, Chinese developers plan a new generation of lower cost large language models targeting broader adoption and reduced computing costs. Competition in artificial intelligence is intensifying.